ArticleJAC-antimicrobial resistance2026
Acquired carbapenemase-producing organisms in North London: health inequalities and healthcare associations, 2016-2023.
Article in JAC-antimicrobial resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acquired carbapenemase-producing organisms (CPO), particularly acquired carbapenemase-producing Enterobacterales (CPE), pose a major public health challenge due to limited treatment options. Objectives: To evaluate associations between CPO positivity and ethnic group, Index of Multiple Deprivation (IMD) and healthcare exposure, and to apply a statistical model to quantify these relationships. Patients and methods: A retrospective observational analysis of CPO cases identified at a London teaching hospital (2016-2023) was conducted. Microbiological, clinical and demographic data were reviewed. Cases were classified as hospital onset healthcare associated (HOHA), community onset healthcare associated (COHA) or community onset community associated (COCA). Socioeconomic status was assessed using IMD. Positive and negative cases were compared by medical specialty, age, sex and ethnicity. Odds ratios for risk factors were estimated, and a mixed-effects logistic regression model was applied. Results: A total of 679 CPO isolates were detected in 651 patients. OXA-48-like (56.1%) and NDM (38.9%) were the predominant carbapenemases. HOHA accounted for 42.1% of cases, COCA for 39% and COHA for 18.9%. Renal, vascular and liver specialties had the highest proportions of CPO-positive patients. Females had 0.8 times the odds of CPO positivity compared with males, and risk increased with age until mid-life. White British patients had 0.62 times the odds of CPO positivity compared with other ethnic groups. IMD analysis showed a bell-shaped distribution, with highest prevalence in mid-deprivation quintiles. Conclusion: CPOs arise from both healthcare-associated and community pathways. Differentiating HOHA, COHA and COCA enhances understanding of local epidemiology and supports targeted infection-prevention strategies including medical specialties.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.